CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Teladoc Health Q3 adj EBITDA beats consensus

By Reuters News


Overview

  • Virtual care provider's Q3 revenue fell 3% yr/yr but beat analyst expectations

  • Q3 adjusted EBITDA rose 14% yr/yr, beating analyst expectations

  • Company's Q3 net loss narrowed compared to prior year


Outlook

  • Teladoc Health expects 2026 revenue of $2.395 bln to $2.441 bln

  • Company sees 2026 adjusted EBITDA between $277 mln and $303 mln

  • Teladoc Health forecasts 2026 net loss per share of $0.95 to $0.75


Result Drivers

  • SEGMENT PERFORMANCE - Integrated Care segment revenue grew, while BetterHelp segment revenue declined due to fewer cash-pay users and focus on insurance-covered services

  • INNOVATION INITIATIVES - Co said Integrated Care segment results benefited from new offerings including Teladoc One, hybrid care and AI-enabled solutions

  • INSURANCE REVENUE - Co said BetterHelp segment insurance revenue exceeded expectations, with progress in expanding provider capacity and access to covered services


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$605.10 mln

$588.48 mln (20 Analysts)

Q3 Loss Per Share

$0.15

Q3 Net Loss

$26.93 mln

Q3 Adjusted EBITDA

Beat

$79.36 mln

$67.76 mln (19 Analysts)

Q3 Loss Per Basic Share

$0.15


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 18 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy."

  • Wall Street's median 12-month price target for Teladoc Health Inc is $7.00, about 8.5% above its October 27 closing price of $6.45


Reuters Recommended Reads

  • Oct 27 - SoFi Technologies Q3 adjusted revenue beats on member, product growth

  • Oct 27 - Universal Health warns of possible impact to annual results from Medicaid changes; Q3 revenue slightly beats

  • Oct 27 - Ensign Group Q3 adjusted EPS beats estimates, revenue up on higher occupancy rates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.